A bill to amend section 303(g) of the Controlled Substances Act (21 U.S.C. 823(g)) to eliminate the separate registration requirement for dispensing narcotic drugs in schedule III, IV, or V, such as buprenorphine, for maintenance or detoxification treatment, and for other purposes.
The bill’s titles are written by its sponsor.
Sponsor and status
Introduced on Jul 10, 2019
This bill is in the first stage of the legislative process. It was introduced into Congress on July 10, 2019. It will typically be considered by committee next before it is possibly sent on to the House or Senate as a whole.
History
|
Jul 10, 2019
|
|
Introduced
Bills and resolutions are referred to committees which debate the bill before possibly sending it on to the whole chamber. |
|
|
If this bill has further action, the following steps may occur next: | |
|
—
|
|
Passed Committee
|
|
—
|
|
Passed Senate
|
|
—
|
|
Passed House
|
|
—
|
|
Signed by the President
|
S. 2074 is a bill in the United States Congress.
A bill must be passed by both the House and Senate in identical form and then be signed by the President to become law.
How to cite this information.
We recommend the following MLA-formatted citation when using the information you see here in academic work:
“S. 2074 — 116th Congress: Mainstreaming Addiction Treatment Act of 2019.” www.GovTrack.us. 2019. July 22, 2019 <https://www.govtrack.us/congress/bills/116/s2074>
- show another citation format:
- APA
- Blue Book
- Wikipedia Template
Where is this information from?
GovTrack automatically collects legislative information from a variety of governmental and non-governmental sources. This page is sourced primarily from Congress.gov, the official portal of the United States Congress. Congress.gov is generally updated one day after events occur, and so legislative activity shown here may be one day behind. Data via the congress project.
